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BACKGROUND: Irritable bowel syndrome (IBS) is a prevalent
functional gastrointestinal disorder. Previous studies have shown
that the burden of illness of IBS is high. It has been suggested
that the quality of life and medical costs of IBS patients are asso-
ciated with the severity of pain. This study aimed to quantify the
burden of illness of IBS in relation to the severity of IBS symp-
toms. METHODS: Patients identiﬁed at community pharmacies
as mebeverine users were administered a questionnaire regard-
ing 1) the Rome II criteria for IBS, 2) predominant type of stool
during symptomatic episodes, 3) severity of symptoms (abdom-
inal pain and discomfort), 4) generic (SF-36) and disease-speciﬁc
quality of life (IBS-QOL), 5) current health status (utilities, 
EQ-5D and SF6D), and 6) loss of productivity. Associations
between severity of symptoms and burden of illness (including
SF-36, IBS-QOL, EQ-5D, SF6D, direct medical cost and loss 
of productivity) were assessed. RESULTS: For 168 patients, 
who met the Rome II criteria for IBS, information on severity 
of symptoms was available. The majority of patients (98, 
58%) were categorized as having severe symptoms of IBS. 47
(28%) patients were suffering from moderate symptoms and 23
(14%) patients had mild symptoms or were asymptomatic. All
components of SF-36 scored lower as the symptom severity
increased. The IBS-QOL score was lower (71.4, 95%CI:
67.5–75.3) for patients with severe symptoms than for patients
with moderate IBS and mild/asymptomatic IBS (81.8, 95%CI:
78.6–85.0 vs. 81.3, 95%CI: 75.5–87.1). The EQ-5D score was
also lower (58.3, CI95% 59.5–65.3) for patients with severe
symptoms compared to the two other groups (68.8 and 66.3).
CONCLUSIONS: This study clearly indicates that the burden of
illness of patients with IBS increases with increasing severity of
symptoms.
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ESOMEPRAZOLE TREATMENT IN PATIENTS WITH
UNINVESTIGATED NON-GERD DYSPEPSIA LEADS TO
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OBJECTIVES: To assess the effect of acid suppression treatment
on patient-reported productivity in uninvestigated non-GERD
dyspepsia. METHODS: A clinical study aimed to investigate
whether response to a 1-week acid suppression trial with
esomeprazole is predictive of the response to four to eight weeks
of esomeprazole therapy was performed in patients with unin-
vestigated non-GERD dyspepsia (patients with predominant
symptoms of pain or burning in the center of the upper abdomen,
and who had not been previously investigated by endoscopy).
Disease-speciﬁc absence from work, reduced productivity while
at work, and reduced productivity while carrying out regular
daily activities were obtained by using the Work Productivity and
Activity Impairment (WPAI) questionnaire. Patients were ran-
domised to double-blind treatment with esomeprazole 40mgqd
or bid for 7 days, followed by either esomeprazole 40mgqd or
placebo for a further 7 weeks. Symptoms were recorded in a
daily diary. RESULTS: Before start of treatment (n = 453),
employed patients (n = 349) reported an average of 2.0 hours
absence from work and 19.8% reduced work productivity (=6.6
hours equivalent; percent reduced productivity ¥ hours actually
worked) during the past week, as well as 26.8% reduced pro-
ductivity in daily activities (all patients). In patients who were
identiﬁed as responders to the 1-week test treatment with
esomeprazole, productivity improvements were all statistically
signiﬁcant (except for hours absent from work) for esomepra-
zole versus placebo after both 4 and 8 weeks of treatment, cor-
responding to a gain of 2.0 to 3.4 work hours and 5.1 to 5.8
percent-units in daily activities per patient and week (p < 0.05).
Further analyses of the relationship between treatment response
and productivity change supported the validity of these results.
CONCLUSION: Effective acid suppression treatment with
esomeprazole in patients with uninvestigated non-GERD dys-
pepsia leads to signiﬁcant improvements in productivity while at
work and in daily activities.
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OBJECTIVES: Regular prophylactic replacement therapy has
been proved to be effective in reducing the bleeding rate and inci-
dence and/or severity of haemophilic arthropathy in children
with severe haemophilia. No study is so far available that eval-
uates efﬁcacy of prophylaxis in adolescents and adults with
haemophilia A. This study is aimed to provide cost effectiveness
evaluation of prophylaxis in adult with haemophilia A.
METHODS: A prospective, open study was designed. Patients
with haemophilia A aged 18 years or more, with frequent bleed-
ing episodes, switching from on-demand treatment to prophy-
laxis, have been enrolled. All patients were treated with a
recombinant B-domain-deleted factor VIII concentrates for all
the 6-month study period. Bleeding event rate and FVIII con-
centrate consumption (that represent 99% of total costs) have
been evaluated over on-demand treatment time period (ODT), 6
months before enrolment, and the prophylaxis time period (PT),
6 months after enrolment. Medical costs have been quantiﬁed
adopting the perspective of the third party payer, i.e. National
Health Service (NHS). RESULTS: Ten patients with a median
age of 34.0 years (23–58 years) were enrolled. Patients reported
a mean of 3.6 during ODT (median = 2.0, 1.5–15) vs. 0.51
events/patient/month during PT (median = 0.16, 0–1.7). Clotting
factor mean consumption was 22,010 during ODT (median =
17,750IU, 4500–50,000) and 28,817IU/patient/month during
PT (median = 28,333IU, 21,333–38,333). Mean cost of con-
centrates in ODT was 10,911 (median = €9607, 2193–23,500)
while during PT was 19,883 €/patient/month (median = 19,550,
14,720–26,450). The mean cost to treat one bleeding in ODT
was 3031. The incremental cost-effectiveness ratio, i.e. the cost
for bleed avoided, was €2803. CONCLUSIONS: These ﬁndings
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showed that prophylaxis in adult patients with haemophilia is
effective in reducing the bleeding rate. Despite the higher cost of
prophylactic treatment compared to on-demand treatment pro-
phylaxis showed to have a good cost-effectiveness ratio.
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OBJECTIVE: Hemophilia is a rare but very expensive disease.
Available treatment strategies have prolonged patients’ life
expectancy and are now focused on improving their quality of
life. We evaluated cost of care of hemophilic patients without
inhibitors. METHODS: The Cost Of Care of Hemophilia
(COCHE) is a naturalistic, multicenter, longitudinal study (time
horizon 8 months) involving moderate and severe patients with
hemophilia A or B. Patients, aged >18 years, without inhibitors,
were sequentially enrolled at 23 Italian Hemophilia Centers.
Information on socio-demographic, clinical, resource absorp-
tion, quality of life and treatment satisfaction was collected. This
analysis pertains on estimate of cost of care with clotting factor
concentrates (perspective of Italian National Health Service, data
expressed as € of 2004). RESULTS: A total of 232 patients were
enrolled (median age = 34.3 years, 18–74), 86.6% had hemo-
philia A, 72.4% were severely affected. At the time of enrolment
81.0% of patients had chronic hepatic C, 25.0% hepatitis B,
15.9% HIV infection. Patients reporting orthopedic problems
were 87.8% and those with target joints were 57.0%. Bleeding
occurred with a mean frequency of 2.Ten hemorrhages/patient/
month (median 1.44, 0–26). At enrolment, 58.5% of the treated
patients were administered recombinant products, with an
increase of 11.4% in 4 months of follow-up. At the enrolment
67.4% of patients were treated on demand and 32.6% on pro-
phylaxis regimen. Patients on demand reported on average 2.26
hemorrhages/patient/month (median = 1.87, 0–8.5), those on
prophylaxis 1.56 hemorrhages/patient/month (median = 0.5,
0–26). Overall, patients cost €8341/patient/month, €4200 those
on demand, €16,473 those on prophylaxis regimen. The incre-
mental cost per avoided hemorrhage in patients on prophylaxis
vs. those on demand was €2123. CONCLUSIONS: Hemophilia
is one of the most expensive diseases: clotting factor concentrates
used to manage hemorrhages and surgery contributes to the most
part of the cost, providing patients with relatively good levels of
quality of life.
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OBJECTIVES: Economic factors are very important in limiting
therapy options for haemophilia, but inadequate treatment lead
to costly consequences having a negative impact on patients’
social integration AIM OF THE STUDY: to evaluate direct
medical costs (therapy and hospitalization) of bleedings, sec-
ondary prophylaxis and surgical interventions; direct non-
medical costs (home-hospital travel costs) and indirect costs
(morbidity costs, loss of income of family members, average
number of days off at scholl/work). METHOD: A total of 224
haemophiliacs registered and treated in Haemophilia Centre
Timisoara and in Clinical Centre for Evaluation and rehabilita-
tion “Christian Serban” Buzias, followed-up during a seven-
years period. 84.38% of the patients had haemophilia A and
15.62%-haemophilia B. Data was obtained from medical charts
and from questionnaires administered to patients. Because in a
developing country an economic analysis is difﬁcult to ascertain,
unitary costs were expressed in €, at average exchange rate com-
municated by the National Romanian Bank for the last year of
the study period. RESULTS: Therapy costs represented 54.56%
of direct medical costs in haemophilia A patients without
inhibitors, 67.13% in haemophilia B- and 87.63% in patients
with high-titer inhibitors. Pseudotumour consumed the highest
ﬁnancial resources in haemophilia A patients and complicated
haematoma was the most costly complication in haemophilia B
patients. Direct non-medical costs represented important per-
cents of mean patient and family income. Mean monthly mor-
bidity cost was €108.28 and loss of income of family members
who forfeid employment in order to offer home care for
haemophilia patients was €81.88/month. Average number of
days off at school/work was 46.64/year, varying according to
haemophilia severity. CONCLUSIONS: Inadequate resource
allocation for haemophilia treatment lead to costly complica-
tions, affecting social integration and leading to important loss
of income, which is responsible for a poor treatment compliance,
all these factors having a strong interactions.
PHM4
UK COST COMPARISON OF BUCY2 CONDITIONING IN
ALLOGENEIC HSCT: ORAL VERSUS IV BUSULFAN
(BUSILVEX®)
Groves LJ1, Hill S2, Nichol A2, Myon E3, Orchard KH1
1Southampton General Hospital, Southampton, Hampshire, England;
2Pierre Fabre Ltd, Winchester, Hampshire, England; 3Pierre Fabre SA,
Boulogne Billancourt, France
Allogeneic HSCT is a cost-intensive procedure. Oral busulfan
(Bu) as part of BuCy2 is a commonly used conditioning regimen
but is associated with high plasma variability. IV Bu has more
predictable pK parameters allowing better targeting of plasma
exposure and reducing hepatic veno-occlusive disease (HVOD)
occurrence, related to blood over-exposure. OBJECTIVES: To
estimate costs of IV versus Oral Bu-based BuCy2 conditioning
in the UK NHS system. METHODS: A simulation based on the
strong correlation established between Bu blood over-exposure
and the occurrence of HVOD (Kashyap A, BB&MT 2002)
included costs of drugs and local HVOD management.
RESULTS: The cost of a full course of oral Bu (1mg/kg ¥ 16)
and IV Bu (0.8mg/kg ¥ 16) is £116.5 and £3220 respectively.
Patients receiving oral Bu have a greater risk of developing
HVOD (20% vs. 5%, p = 0.03, Kashyap 2002). In Southamp-
ton the cost of managing HVOD was estimated to be £11,050
per case (based on additional in-patient stay, drug treatment and
medical management), generating an extra cost per patient of
£2210 (£11,050 ¥ 0.2) and £552.50 (£11,050 ¥ 0.05) respec-
tively. Therefore the total estimated cost using oral Bu compared
to IV Bu in BuCy2 is £2326.50 and £3772.50 respectively. From
an initial cost ratio of 1/27.6 in favor of oral Bu (drug costs only)
the ratio dropped to 1/1.6 when the cost of HVOD management
was included in the simulation. CONCLUSIONS: The additional
cost of £1446 with IV Bu is relatively modest in the context of
better targeting of the therapeutic window, potential superior
transplant outcome, and better time allocation of health care per-
sonnel (easier administration, patient monitoring and treatment
compliance) seen with Busilvex®.
